Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HEALTHCARE (NY:XLV)

128.77 -3.10 (-2.35%)
Official Closing Price Updated: 8:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
30 31 Next >
Playbook Revisited As UNH Beat Could Help Sagging Healthcare Stocks
Last week saw a broadening of the rally as many top sectors were up over 3%. But healthcare was among the laggards up only 0.7%. 
Via Talk Markets
Developing Your Uniqueness As A Trader
Via Talk Markets
2023 Midyear Review Of Index ETFs And Smart Beta Strategies & A Tribute To Harry Markowitz
A review and analysis of the first 6 months of 2023 using benchmark ETFs, Sector ETFs, and Smart Beta ETFs and what is likely to follow next. 
Via Talk Markets
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout. 
Via MarketBeat
Exposures Product Safety
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
$1 Billion Deal For Moderna To Expand Product Pipeline in China
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher 
Via MarketBeat
Topics ETFs Economy
Exposures COVID-19 Economy
Bullish Action: Chipotle, Visa, Stryker Break Through Resistance
Chipotle, Visa, and Stryker recently broke out of chart bases, and remain in buy range on strong fundamental growth, institutional buying and analyst upgrades. 
Via MarketBeat
Biotech Blues: Stay Balanced Through July Earnings Season
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
S&P 500 Rallies Back To Highs As Apple, Nvidia Lead, But Watch For This; Tesla Deliveries Due
Many stocks flashed buy signals. But was the pullback over too quickly? 
Via Investor's Business Daily
Biotech And Healthcare Stocks Lagging
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
D.R. Horton, Shake Shack And A Home Construction Company Up 32% This Year: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc. 
Via Benzinga
Medical Stocks Waters, Agilent, Illumina Show Growth Potential
Medical-sector stocks Waters, Agilent, and Illumina appear to be trading at low valuations relative to their future growth prospects, according to analysts. 
Via MarketBeat
Countdown To ES Downleg
The current rally is built on the false notion that recession has been and would be avoided, that earnings would start to rise, and that incoming data aren‘t generally bad. 
Via Talk Markets
More Balanced June
Heading into the month of June, stock market performance this year was a clear case of the haves and the have-nots. 
Via Talk Markets
Wary Of Bull Market Chorus
We‘re still in the euphoric stage of the rally that has a bit further to run, in spite of the wide Nasdaq vs. long-dated Treasury yields disconnect. 
Via Talk Markets
S&P 500 Low Volatility Index May 2023 Rebalance
Since the last rebalance for the S&P 500 Low Volatility Index on Feb. 17, 2023, the S&P 500 finished up 3.2% despite briefly dropping in mid-March. 
Via Talk Markets
Two Charts That Can Help You See What’s To Come For The Markets
While a handful of large companies have driven the stock market gains, the vast majority of stocks are down. 
Via Talk Markets
Bearish Vision As Apple Tests All-Time High
Apple's first new product category in 8 years is a mixed-reality headset for $3499. 
Via Talk Markets
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Corporate Bankruptcies At Levels Last Seen During The Pandemic
Despite all of the mainstream talk about a strong, resilient economy, corporate bankruptcies through the first four months of 2023 came in at the highest level since 2010. 
Via Talk Markets
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
Tech In Orbit
Tech has led the way higher with a sharp move this week. The sector is now extremely overbought, trading 3.23 standard deviations above its 50-DMA; the fifth most overbought reading on record. 
Via Talk Markets
A Good Week For The Market But A Pause In The Biotech Rally
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
Your Mid-May Market Update: Sector Strength And Weakness So Far In 2023
Today's session continued the ongoing theme of 
Via Talk Markets
Good Odds And Odd Goods
Investing is all about making money. It is the realm where you go find out where the odds are good, even if the goods are odd. 
Via Talk Markets
5 Most-Loved ETFs Of Last Week
Last week was marked by volatility. Overall, ETFs pulled in a modest $260 million in capital for the week, bringing total inflows of $111.7 billion year to date. 
Via Talk Markets
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Seasonal Mid Point
The next three months, which is the period straddling the back half of spring and the first half of summer, has been relatively strong in the last ten years. 
Via Talk Markets
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
6 Best Healthcare Stocks to Buy Right Now
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat. 
Via MarketBeat
Topics Economy Intellectual Property
Exposures Economy Intellectual Property Product Safety
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.